Pfizer Inc.
Discovers, develops, manufactures and markets a broad portfolio of biopharmaceutical products including vaccines, oncology therapies, and treatments for cardiovascular, inflammation, rare disease and infectious conditions.
As of Oct 16, 2026
Summary
Pfizer Inc. is a pharmaceutical company that develops and manufactures medicines and vaccines for a range of health conditions. The stock is currently trading at $29.58 with a bullish technical bias and has gained 7.0 percent over the past month and 29.8 percent over the past year, reflecting notable upward momentum across both timeframes.
Price history
As of Oct 16, 2026
Performance
+0.44%
+4.60%
+7.02%
+21.61%
+24.93%
+29.78%
As of Oct 16, 2026
Technical indicators
- 69.8
- 0.13Bullish
- 50: 27.97 · 200: 26.03Bullish
- $27.64 / $29.88
Technical Bias
Bullish lean
Pfizer's technical setup is tilted bullish right now. The MACD is positive and the price sits above both the 50-day and 200-day moving averages, whereas the RSI reads neutral at 69.8. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 16, 2026
Fundamentals
- $166B
- 38.43
- $0.76
- 6.80%
- +2.6%
- $9.08B
- 0.28
- $22.57 – $29.88
- 6.06%
- Nov 6, 2026
- Nov 3, 2026 (16 days)
As of Oct 18, 2026
Upcoming catalysts
- Earnings report
- Ex-dividend date
As of Oct 18, 2026
Latest news
As of Oct 18, 2026
MonkeyTrade's Take on Pfizer Inc.
Short-term outlook
Pfizer's short-term setup leans bullish: MACD is positive, both the 50-day and 200-day moving averages sit below the current price, and shares are up 7.0% over the past month. RSI at 69.8 is creeping toward overbought, so a pause or pullback toward the $27.64 support level wouldn't be surprising, while a push through $29.88 resistance would confirm the uptrend is still in control. With earnings not due until November 3, 2026, there's no near-term catalyst to disrupt this technical picture.
Medium-term outlook
Pfizer's thin 2.6% revenue growth and modest 6.8% margin sit awkwardly against a 38.43 P/E, suggesting the market is paying up for a recovery that hasn't shown in the numbers yet. The 6.1% dividend yield gives income investors a reason to stay patient, and the bullish technical lean suggests sentiment is already tilting ahead of fundamentals. A sustained pickup in revenue growth would be the trigger to justify the current valuation over the coming quarters.
Key risks
- Pfizer's profit margin sits at a thin 6.8% alongside only 2.6% revenue growth, leaving little room for error if costs rise or sales slow.
- The stock trades at 38.43 times earnings while reportedly paying out over 226% of earnings in dividends, a gap worth watching for sustainability.
- Pfizer operates in a highly competitive pharmaceutical landscape, with peers like Moderna and emerging players such as Roivant Sciences drawing attention to pipeline and catalyst developments.
- Shares are trading near the top of their 52-week range at $29.58 against a high of $29.88, which can increase sensitivity to any disappointing news.
About Pfizer Inc.
Pfizer Inc. (NYSE: PFE) is one of the world's largest pharmaceutical companies, operating in the Healthcare sector under the Drug Manufacturers - General industry. With a market capitalisation of $166B, Pfizer ranks among the major players in global drug development and manufacturing, holding a significant position in an industry defined by research-driven competition and long product cycles.
Pfizer's key figures offer a window into how the market currently views the stock. A price-to-earnings ratio of 38.43 suggests investors are pricing in expectations tied to future earnings relative to current profits. Meanwhile, a dividend yield of +6.1% stands out as notably high, reflecting the company's long-standing approach of returning cash to shareholders. Together, these figures paint a picture of a mature, income-oriented company operating within a closely watched sector of the broader healthcare market.
How to trade Pfizer Inc.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.